

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 14, 2020**

**Sarepta Therapeutics, Inc.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-14895**

(Commission File Number)

**93-0797222**  
(IRS Employer  
Identification No.)

**215 First Street  
Suite 415**

**Cambridge, MA 02142**

(Address of principal executive offices, including zip code)

**Registrant's Telephone Number, Including Area Code: (617) 274-4000**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, Par Value \$0.0001 per share	SRPT	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On February 14, 2020, Sarepta Therapeutics Three, LLC, a subsidiary of Sarepta Therapeutics, Inc. (“Sarepta”), and F. Hoffman-La Roche Ltd (“Roche”) closed the transactions contemplated by that certain License, Collaboration, and Option Agreement, dated as of December 21, 2019 (the “Collaboration Agreement”).

Also on February 14, 2020, Sarepta and Roche Finance Ltd, an affiliate of Roche, closed the transactions contemplated by that certain Stock Purchase Agreement, dated as of December 21, 2019 (the “Stock Purchase Agreement”).

Sarepta previously disclosed the entry into the Collaboration Agreement and the Stock Purchase Agreement in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 23, 2019. Additional details regarding the transactions contemplated by the Collaboration Agreement and the Stock Purchase Agreement can be found therein.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**Sarepta Therapeutics, Inc.**

Date: February 18, 2020

By: /s/ Douglas S. Ingram

Douglas S. Ingram

President and Chief Executive Officer